Antiphospholipid syndrome (APS) is described as a common risk factor for recurrent thromboembolic events and/or pregnancy complications resulting from circulating antiphospholipid antibodies (aPLA)(1). It is now widely accepted that the plasma phospholipid binding protein β-2-Glycoprotein 1 (β2GP1) is the main antigenic target for aPLA (2). β2GP1 is a protein of 43 kDa composed of 5 short consensus repeat domains called “sushi” domains. An overactive immune system produces anti-β2GP1 that is associated with recurrent clotting events (thrombosis) including premature stroke, myocardial infarction, repeated miscarriages, phlebitis, venous thrombosis and pulmonary thromboembolism.

​

Although young and middle-aged adults, between the ages of 15 and 50 represent 85 % of APS patients, people from all age groups can also be affected. While largely under-diagnosed, it is estimated that 1 in 100 people have the disorder. Early diagnosis of APS is therefore crucial for proper and efficient care (4).

​

Currently no specific treatments exist for APS, though management by anticoagulation therapies  is aimed at preventing thrombosis.

​